stockportfolio.pro
Amneal Pharmaceuticals, Inc. (AMRX)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Amneal Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $1.03B | $1.66B | $1.63B | $1.99B | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| Gross profit | $597.46M | $526.18M | $716.40M | $353.00M | $628.39M | $768.97M | $784.71M | $820.57M | $1.02B | $1.11B |
| Net income | $0 | $0 | $-19.74M | $-603.57M | $67.79M | $13.16M | $-270.58M | $-83.99M | $-116.89M | $72.06M |
| Net margin | 0.0% | 0.0% | -1.2% | -37.1% | 3.4% | 0.6% | -12.2% | -3.5% | -4.2% | 2.4% |
Source: Amneal Pharmaceuticals, Inc. SEC filings (10-K).
Explore 10 years of Amneal Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AMRX in your portfolio →
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Amneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.02B for fiscal year 2025, up 8.0% from the prior year, according to its SEC filings.
Is Amneal Pharmaceuticals, Inc. profitable?
Yes. AMRX earned net income of $72.06M in fiscal 2025, a net margin of 2.4%.
What is AMRX's P/E ratio?
Amneal Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 41.3 based on the latest data in our nightly-refreshed cache.
How fast is Amneal Pharmaceuticals, Inc. growing?
AMRX's revenue grew at roughly 8.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.